Generic Version of Advair
The generic version of Advair (fluticasone propionate/salmeterol) is Wixela Inhub, which was approved by the FDA in 2019 as the first substitutable generic maintenance inhaler for asthma and COPD. 1
Available Generic Formulations
- Wixela Inhub is a dry powder inhaler manufactured by Viatris that delivers the same fixed-dose combination of fluticasone propionate and salmeterol as the brand-name Advair Diskus 1, 2
- The generic is available in the same strengths as Advair Diskus, including the 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg formulations 3, 4
Evidence of Bioequivalence and Clinical Performance
Bioequivalence has been formally established between Wixela Inhub and Advair Diskus, meeting FDA requirements for substitutable generic approval 2. The FDA applied a "weight-of-evidence" approach for this complex generic product, requiring manufacturers to perform randomized controlled trials in patients with asthma (though approval was granted for both asthma and COPD indications) 1.
Real-World Effectiveness Data
A large propensity score-matched cohort study of 45,369 patients (creating 10,012 matched pairs) demonstrated that:
- Wixela Inhub showed nearly identical effectiveness to Advair Diskus for preventing moderate or severe COPD exacerbations (hazard ratio 0.97,95% CI: 0.90-1.04) 1
- Safety profiles were equivalent, with similar rates of pneumonia hospitalization (hazard ratio 0.99,95% CI: 0.86-1.15) 1
Device Performance Characteristics
The Inhub inhaler device has been rigorously tested and demonstrates:
- Consistent dose delivery across varying patient inspiratory capabilities, including patients with severe COPD who have reduced inspiratory flow rates (60.8-84.9 L/min) 5
- Low flow dependency for both fluticasone propionate and salmeterol delivery, ensuring reliable dosing even in patients with compromised lung function 5
- Device robustness maintained after 21.5 days of twice-daily use, meeting all FDA specifications for quality parameters including assay, delivered dose uniformity, and aerodynamic size distribution 4
- Ease of use demonstrated in patients who were both dry powder inhaler-experienced and dry powder inhaler-naive, even without training beyond the instructions for use 4
Clinical Context for Use
The combination of fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-agonist) remains a cornerstone therapy for:
- Moderate to severe persistent asthma requiring step 3 or higher treatment, where the combination is preferred over increasing inhaled corticosteroid doses alone 6, 7
- COPD with elevated eosinophilia or frequent exacerbations uncontrolled by bronchodilators alone 2
Important Safety Considerations
- Long-acting beta-agonists should never be used as monotherapy for asthma control; they must always be combined with inhaled corticosteroids due to increased risk of severe exacerbations and deaths when used alone 6
- The combination therapy carries a 4% increased risk of pneumonia compared to long-acting beta-agonist therapy alone in COPD patients 8
Pharmacokinetic Profile
Both the generic and brand formulations demonstrate similar pharmacokinetic characteristics:
- Fluticasone propionate has high plasma protein binding (99%), extensive first-pass metabolism via CYP3A4, and a terminal half-life of approximately 5.6 hours 9
- Salmeterol has very high plasma protein binding (96%), extensive metabolism via CYP3A4 to α-hydroxysalmeterol, and a terminal half-life of approximately 5.5 hours 9
- Population pharmacokinetic analyses show no clinically relevant effects of age, gender, race, or body weight on drug clearance for either component 9